NCT06530082View on ClinicalTrials.gov

A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

January 1, 2027

Conditions
Breast Neoplasms
Interventions
BIOLOGICAL

CircFam53B-219aa DC vaccine

Dendritic cell vaccine loaded with circular RNA-encoded cryptic peptide. Administer intradermally once every 3 weeks according to a dose-escalation gradient of 0.5-1×10⁷, 1.5-2×10⁷, and 4-5×10⁷ cells.

DRUG

camrelizumab

Camrelizumab for Injection, 200 mg IV infusion, administered once every 3 weeks.

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT06530082 - A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer | Biotech Hunter | Biotech Hunter